A ngiogenesis, or new blood vessel formation, is integral to many physiological processes, such as wound healing and placental development, but also to disease states such as tumorigenesis (1) , inflammatory conditions (2) , and rheumatoid arthritis (RA) 4 (3) (4) (5) . The process of angiogenesis is controlled by a complex interaction of inhibitors and activators, and an inappropriate balance leads to the initiation and maintenance of angiogenesis. Some of these proinflammatory mediators include cytokines, chemokines, adhesion molecules, growth factors, and extracellular matrix receptors (6) . Specifically, some known angiogenic stimuli include growth factors (7, 8) such as basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) (9) , TNF-␣ (10), C-X-C chemokines (11, 12) such as IL-8 or epithelial neutrophil-activating peptide (ENA-78), fractalkine (13) , and adhesion molecules such as soluble E-selectin or soluble VCAM-1 (14) .
IL-18 is a cytokine with many proinflammatory functions. IL-18 was initially described as IFN-␥-inducing factor in 1989 (15) . Thus, IL-18 stimulates Th1 cytokines by T cells and NK cells and promotes Th1 cell differentiation and immune responses (16, 17) .
IL-18 can act in synergy with IL-12 in regulating IFN-␥ (18). However, IL-18 also up-regulates other cytokines, such as TNF-␣, IL-1␤, and IL-8 in non-CD14
ϩ PBMCs, resting T cells, and NK cells (19) . IL-18 up-regulates GM-CSF in PBMCs (20) and also in synovial membrane cultures, directly affecting macrophages to stimulate cytokine production (21) .
IL-18 has structural homology with IL-1, shares some common signaling pathways (22) , and also requires the cleavage at its aspartic acid residue by IL-1-converting enzyme to become the active, mature protein (23, 24) . Thus, IL-1 and IL-18 share many biologically similar inflammatory functions. Previous work has implicated IL-18 in RA, as higher levels are present in RA vs osteoarthritic synovial fluid (SF) and sera (21) . Also, IL-18 enhanced erosive, inflammatory arthritis in a murine model of systemic arthritis (21) . In the study by Leung et al. (25) in which IL-18 promoted collagen-induced inflammatory arthritis through a mechanism shown to be distinct from IL-12, cytokine treatment enhanced synovial hyperplasia, inflammatory infiltrate, and cartilage erosion. Interestingly, the IL-18-treated mice produced significant amounts of TNF-␣, and splenic macrophages from mice cultured with IL-18 also stimulated high levels of TNF-␣. The influential role of IL-18 in articular inflammation was confirmed in mice lacking the IL-18 gene that had reduced incidence and severity of collagen-induced arthritis, which was reversed by treatment with rIL-18 (26) . One important source of IL-18 is the macrophage, which is a critical synovial tissue producer of IL-12 (27) , and responsible for the production of many other cytokines (28) . However, various other sources of IL-18 have been identified, including Kupffer cells, dendritic cells, keratinocytes, articular chondrocytes, osteoblasts, and synovial fibroblasts (18, 21, 29 -33) .
In regard to arthritis, if IL-18 functions in an autocrine or paracrine fashion, the increased expression of IL-18 in the synovium may play a critical role in the development of synovial inflammation, synovial hyperplasia, and articular degradation, to which angiogenesis may contribute. Given the importance of angiogenesis in the pathophysiology of RA, we hypothesized a role for IL-18 as an angiogenic mediator. Supportive of this function is the finding that IL-18 has been shown to stimulate production of angiogenic TNF-␣ (19) . The establishment of the role of IL-18 in inflammation and RA led to the question of its angiogenic potential.
In this study, we examined the capacity of IL-18 to mediate angiogenesis in in vitro and in vivo models. We further compared the angiogenic activity of IL-18 with that of known mediators, such as bFGF. One potential mechanism of the angiogenic activity of IL-18 that we examined is through the involvement of ␣ v ␤ 3 integrin (34) . This role of ␣ v ␤ 3 was examined in the IL-18-induced migration of endothelial cells. IL-18 induced tube formation in Matrigel matrix in vitro. To examine the role of IL-18 in angiogenesis in vivo, we also implanted IL-18 in Matrigel plugs in mice, and found a significant increase in blood vessel formation over control, as measured by hemoglobin concentration. This effect was not decreased by implanting neutralizing anti-TNF-␣ Ab in the Matrigel plug. Finally, in an alternative model of angiogenesis, a wound granuloma model, we implanted sponge discs embedded with IL-18 into mice and showed a 4-fold increase in angiogenesis compared with controls. These findings support a novel role for IL-18 as an angiogenic mediator in RA and may elucidate a potential therapeutic target for angiogenesis-directed disease.
Materials and Methods

Reagents
Recombinant human (rh) IL-1␤ and TNF-␣, with sp. act. of 2 ϫ 10 7 and 1.3 ϫ 10 7 U/mg, respectively, were gifts from Upjohn-Pharmacia (Kalamazoo, MI). Some TNF-␣ was from R&D Systems (Minneapolis, MN). rhIL-18 was purchased from R&D Systems, with sp. act. measured by ability to induce IFN-␥ produced by KG-1 cells in the presence of 10 ng/ml rhTNF-␣ (100 ng/ml rhIL-18 induces 0.5-2 ng/ml IFN-␥ produced by 10 5 /ml KG-1 cells), and was used for the majority of the assays. An additional source of rhIL-18 was PeproTech (Rocky Hill, NJ), with IL-18 sp. act. determined by the dose-dependent stimulation of IFN-␥ production by human PBMC costimulated with human IL-12 (ED 50 of 5 ng/ml); and the experiments in which this IL-18 was used included the checkerboard assay, the chemotaxis assays comparing the activity of IL-18 with IL-8 or epithelial neutrophil-activating peptide-78 (ENA-78), and the Matrigel in vivo assays with IL-18 and anti-TNF-␣ Ab. PeproTech was also the source for the rhIL-8 and ENA-78, with biological activities determined by significant ability to chemoattract human peripheral blood neutrophils using a concentration of 10 -100 ng/ml and 5-10 ng/ml, respectively. Neutralizing monoclonal mouse anti-human IL-8, mouse anti-human ENA-78, and polyclonal goat anti-human IL-18 Ab were obtained from R&D Systems. Neutralizing mouse anti-TNF-␣ was obtained from R&D Systems. Monoclonal mouse anti-human integrin ␣ v ␤ 3 (vitronectin receptor) was obtained from BioWhittaker Clonetics (Temecula, CA). Nonimmune rabbit serum (R&D Systems) and mouse serum IgG (PharMingen, San Diego, CA) were negative controls. Nonspecific goat IgG control from R&D Systems was also used. Recombinant bovine acidic FGF (aFGF) and recombinant human bFGF with sp. act. defined as ED 50 of 0.1-0.3 ng/ml and 0.1-0.25 ng/ml were purchased from R&D Systems. Recombinant VEGF was obtained from Endogen (Woburn, MA). Growth factor-reduced Matrigel Matrix, derived from Engelbreth-Holm-Swarm mouse tumor, was purchased from Becton Dickinson (Bedford, MA). Human microvascular endothelial cells (HMVECs) were obtained from Clonetics (San Diego, CA). Diff-Quik was purchased from Baxter (North Chicago, IL). A Kontes' homogenizer was obtained from Kontes Glass (Vineland, NJ); tetramethylbenzidine and methemoglobin were obtained from Sigma (St. Louis, MO); and ethylene vinyl acetate copolymer was obtained from Elvax (Dupont, Wilmington, DE).
Patient population
SFs were isolated from patients with RA during therapeutic arthrocentesis. RA SFs were used for HMVEC migration assays. All specimens were obtained with Institutional Review Board approval.
Bioassay for HMVEC migration activity
Subconfluent HMVECs (passage [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] were fed the night before the assay, to optimize the cellular conditions, with endothelial cell basal medium-2 (EBM-2; Clonetics) and 0.1% FBS. HMVECs (3.75 ϫ 10 4 cells/25 l EBM and 0.1% FBS) were placed in the bottom wells of a 48-well Boyden chemotaxis chamber (NeuroProbe, Cabin John, MD) with gelatin-coated polycarbonate membranes (8 m pore size; Nucleopore, Pleasant, CA) (14) . The chamber was inverted and incubated in a humidified incubator with 5% CO 2 /95% air at 37°C for 2 h, allowing endothelial cell attachment to the membrane. The chamber was reinverted, and the test substances, PBS, positive control bFGF (60 nM) in PBS, or RA SF were added to the wells in the top of the chamber, and the chamber was further incubated for 2 h at 37°C. IL-18 (R&D Systems) was used in varying concentrations (11.25 ng/ml or 0.625 nM to 180 ng/ml or 10 nM). PBS served as the negative control throughout these experiments, and testing PBS with 2% BSA, the diluent used to reconstitute the lyophilized cytokines, resulted in similar baseline levels of HMVEC migration. Additionally, this assay was also performed with a representative RA SF sample after incubation for 1 h at 37°C with combinations of neutralizing Ab (25 g/ml) to human IL-18 and ENA-78 or IL-8 before adding samples to the bottom of the wells.
Comparison was made to control nonspecific Abs, goat IgG for anti-IL-18 control, and mouse IgG for anti-IL-8 and anti-ENA-78. A confirmatory assay was performed with rhIL-18 and the addition of neutralizing antihuman IL-18 Ab or nonspecific isotype-matched control Ab (25 g/ml of each). A comparative dose response to the cytokines IL-18, IL-8, and ENA-78 (PeproTech) was also examined. The membranes were then removed, fixed in methanol for 1 min, and stained with Diff-Quik. Readings represent the number of cells migrating through the membrane (the sum of three high power ϫ40 fields/well, averaged for each quadruplicate well).
Checkerboard analysis
Checkerboard analyses were performed as previously described (14, 35) using the Boyden chamber. Briefly, increasing concentrations of IL-18 (0, 1, 10, and 100 nM) were added to the cell suspensions in the bottom wells in addition to the top wells. The effect of an alteration or decrease in the resultant gradient was examined. The assay was performed three times and analyzed in a similar manner as above.
The role of ␣ v ␤ 3 integrin in IL-18-mediated migration
To determine whether IL-18 induces endothelial migration via ␣ v ␤ 3 integrin, we employed the modified Boyden chamber migration assay. HMVECs were preincubated for 1 h at 37°C with Ab to integrin ␣ v ␤ 3 (25 g/ml), in an attempt to inhibit its function in the migration process, or nonspecific isotype-matched control Ab. The cell suspensions were then incubated again with Ab to ␣ v ␤ 3 or nonspecific Ab and used in the cell migration assay, as described above. The test substances included IL-18 (10 nM), bFGF (60 nM) as positive control, and PBS as negative control. This assay was performed three times, with additional positive control TNF-␣ (15 ng/ml) or negative control VEGF (10 ng/ml).
IL-18 induced HMVEC proliferation
HMVEC proliferation in response to rhIL-18 was determined using a modified method from previously described procedures (14, 36) . Briefly, HMVECs fed 1 day before use (with a fresh media exchange to obtain optimal growth conditions) were trypsinized and resuspended at 5 ϫ 10 4 cells/ml in EBM (Clonetics) ϩ 2% FBS ϩ gentamicin. An equivalent number of cells (2.5 ϫ 10
3 ) in 50 l cell suspension was plated nonconfluently onto each well of a 96-well plate and allowed to adhere for 4 h at 37°C. Serial IL-18 dilutions were prepared in this media at 2ϫ concentration, of which 50 l was added to the 50 l cell suspension already in the wells, resulting in 100 l 1ϫ dilutions. In a similar manner, serial dilutions of bFGF were also prepared for a positive control; media alone were added for the negative control. All dilutions were performed in quadruplicate wells. The plate was incubated for up to 72 h at 37°C. The Cell Titer 96 Aqueous nonradioactive cell proliferation assay kit (Promega, Madison, WI), which contains a tetrazolium compound and phenazine methosulfate solution, was diluted according to the recommended protocol and added to each well (20 l/well). The plates were incubated at 37°C for 2-12 h until color development occurred. Absorbance was read at 490 nm on an ELISA plate reader with Microplate Manager (Bio-Rad, Richmond, CA). The absorbance readings were performed when the maximal response (plateau y-axis value) by bFGF concentrations represented at least a doubling from baseline control (no stimulation), and the absorbance at 490 nm (y-axis) vs concentration of stimulant (x-axis) was plotted and examined. Proliferation curves for HMVECs were determined, and measurements were obtained and compared in the log proliferation phase, which was 3 days (t ϭ 72 h) for the conditions described. Serial dilutions of IL-18, ranging from 1 fM to 100 nM, or bFGF (positive control), ranging from 10 fM to 100 nM, in EBM and 2% FBS in a 100-l vol were assayed.
Matrigel in vitro HMVEC tube formation assay for in vitro angiogenesis
Matrigel was used to examine HMVEC tube formation in response to IL-18. Matrigel was plated in eight-well chamber slides after thawing on ice, and the Matrigel was allowed to polymerize at 37°C for 30 -60 min. HMVECs were removed from culture, trypsinized, and resuspended at 4 ϫ 10 4 cells/ml in Medium 199 (Invitrogen, Carlsbad, CA) containing 2% FBS and 200 g/ml endothelial cell growth supplement (Becton Dickinson, Bedford, MA). Four hundred microliters of cell suspension were added to each chamber, followed by 1, 5, or 10 nM IL-18, 50 nM PMA, or vehicle control (PBS for IL-18, and DMSO for PMA) placed directly into the suspension in the chambers. The chamber slides were then incubated for 16 -18 h at 37°C in 5% CO 2 humidified atmosphere. Culture media were aspirated off the Matrigel surface, and the cells were fixed with methanol and stained with Diff-Quick Solution II. Each chamber was photographed using Polaroid Microcam camera at ϫ22 magnification. The number of tubes formed was quantitated blindly, as previously described (36) . Briefly, a connecting branch between two discrete endothelial cells was counted as one tube and required a consistent intensity, thickness, and minimum length (Ͼ1 mm on a 4ϫ enlarged copy of the photomicrograph) to be counted. This tube analysis was determined from one focal plane generated from a photomicrograph of the center of the well, focusing on the surface of the Matrigel, which was also the most prominent portion of the Matrigel (Ͻ0.5 cm deep after pipetting 400 l into the chamber). Each concentration of the test substance and vehicle control was performed in triplicate within the same chamber, while PMA and its vehicle DMSO were tested in the chamber's remaining two wells. This assay was performed four times for each IL-18 concentration.
Matrigel plug angiogenesis in vivo assay
To examine the effect of IL-18 on angiogenesis in vivo, we used a Matrigel plug assay (37, 38) . C57BL/6 mice were anesthetized by Metofane inhalation. Each mouse was shaved on its ventral aspect and given an s.c. injection of sterile Matrigel (500 l/injection) with a 27-gauge needle. Matrigel plus PBS served as the negative control, Matrigel containing bovine aFGF (1 ng/ml) served as the positive control, and Matrigel with IL-18 (10 nM) was the test substance. After 7-10 days, the mice were sacrificed by Metofane inhalation. The Matrigel plugs were then carefully dissected out, with removal of any surrounding connective tissue, and then analyzed by hemoglobin measurement or by histology. The Drabkin's reagent method of determining hemoglobin content was employed. For histological analysis, we also embedded some of these plugs in paraffin for tissue sectioning and staining.
Additionally, we examined the effect of IL-18 in the presence of neutralizing anti-TNF-␣ Ab in the Matigel plug. Although the aim of this experiment was not to block endogenous TNF-␣ completely with the dose employed, the effect of IL-18 while inhibiting the local activity of TNF-␣ on angiogenesis at the site of the Matrigel was assessed. Matrigel plugs containing 10 nM IL-18 (PeproTech) and 25 g/ml anti-TNF-␣ Ab or isotype-matched control IgG were injected into mice (n ϭ 18 per group). Matrigel with PBS also served as a negative control.
Hemoglobin determination of angiogenesis in Matrigel plugs
The Matrigel plugs dissected from the mice were carefully stripped of any remaining peritoneum. The plugs were weighed by placing them into preweighed 1-ml tube of ddH 2 0 and homogenized for 5-10 min on ice. The samples were spun at 10,000 rpm on a microcentrifuge for 6 min, and the supernatants collected for hemoglobin measurement. Fifty microliters of supernatant were mixed with 950 l Drabkin's reagent and allowed to sit at room temperature for 15-30 min, and then 100 l of this mixture was placed in a 96-well plate. Absorbance was read with a Microplate Manager ELISA reader at 540 nm. Hemoglobin concentration was determined by comparison with a standard curve in g/dl. These values were normalized by dividing the hemoglobin percentage by the plug weight. Hemoglobin concentration is a reflection of the number of blood vessels in the plugs.
For the Matrigel in vivo experiments comparing plugs containing IL-18 and anti-TNF-␣ or IL-18 and control Ab, the hemoglobin concentrations were determined by the tetramethylbenzidine method (39, 40) . In brief, methemoglobin (17.5 mg) in 25 ml double-distilled water was brought to room temperature, and glycerol 30% was added. Serial dilutions were prepared to generate a standard curve. Fifty microliters of supernatant or standard were added to a 96-well plate in duplicate, 50 l tetramethylbenzidine was added to each sample, the plate was allowed to develop at room temperature for 15-20 min with gentle shaking, and the reaction was terminated with 150 l 2 N H 2 SO 4 after 3-5 min. Absorbance was read with an ELISA plate reader at 450 nm. To calculate hemoglobin concentrations, the values were normalized by the weight of the plugs.
Masson's trichrome staining of Matrigel plugs
To examine the Matrigel plugs histologically, some of the plugs were paraffin embedded. Sections (5 m) were deparaffinized and stained using Masson's trichrome straining. In brief, sections were hydrated in distilled water, dipped in Bouin's solution for 1 h at 56°C, washed in water, dipped in Weigert's iron solution for 7 min, washed, and dipped in Biebrich scarlet-acid fuchsin solution for 2 min. Sections were then rinsed, incubated in phosphomolybdic-phosphotungstic acid solution for 10 min, dipped in aniline blue solution for 5 min, rinsed, dipped in glacial acetic acid solution for 3-5 min, and dehydrated in two changes of 95% alcohol, 100% alcohol, and xylene. The slides were mounted with Cytoseal 60 (Stephens Scientific, Kalamazoo, MI).
Sponge granuloma in vivo angiogenesis assay
The animal model of inflammatory angiogenesis using a sponge granuloma has been described by Fajardo and colleagues (41) . C57BL/6 mice were divided into several groups: negative control PBS; positive control, aFGF; and test substance, IL-18. One-centimeter sponge discs cut from sheets of 2-mm-thick polyvinyl alcohol foam sponges obtained from sterile packs (M-pact, Eudora, KS) were prepared, and a 2-mm hole was cut into the disc center to serve as a depot for control PBS or test substances, and then closed back with the cut plug. After adding the stimulant to the center hole, the sponge discs were coated with an inert slow release ethylene vinyl acetate copolymer, Elvax (DuPont Packages), and both disc surfaces were sealed with Millipore filters (0.45 m) using Millipore glue number 1 (Millipore, Bedford, MA). The animals were anesthetized with pentobarbital 40 mg/kg of body weight, the hair on their left back area was shaved and sprayed with 70% ethanol, and the disc inserted into the s.c. layer at a site 2 cm distant from the incision, which was then sutured to prevent disc dispersion. After 9 -12 days, the animals were sacrificed, and the sponge discs were harvested. The sponges were then analyzed by hemoglobin quantitation.
Hemoglobin quantitation of sponge granulomas by tetramethylbenzidine
To quantitate angiogenesis in the sponge model, the sponges were placed in 2 ml double-distilled water in 24-well plates. The sponges were cut into small pieces with scissors and then homogenized with a Kontes' homgenizer. The samples were then spun at 8000 rpm for 6 min, and the resultant supernatants were filtered through a 0.22-m filter. The hemoglobin percentage was determined by tetramethylbenzidine (39, 40) . The protocol as described for the hemoglobin concentration determination in the Matrigel plug assay above was then followed, in this case using 50 l of the filtered supernatant. To calculate hemoglobin concentrations, the values were normalized by the weight of the sponges.
Statistical analysis
Statistical analysis was performed using the nonparametric Wilcoxon ranksum test, with statistical significance defined by p Ͻ 0.05. Values were expressed as means Ϯ SEM.
Results
IL-18 induces HMVEC migration
To determine the effect of rhIL-18 on HMVEC migration, we tested varying concentrations of IL-18 in a modified Boyden chamber assay. A representative assay of three is shown (Fig. 1 
Neutralization of IL-18 inhibits HMVEC migration
To confirm the specificity of rhIL-18-induced HMVEC migration, we preincubated the IL-18 stimulant with either neutralizing goat anti-human IL-18 IgG Ab or nonspecific isotype-matched control IgG Ab, at a concentration of 25 g/ml for 1 h before and during the 2 h of the cell migration assay. The response to the stimulant with or without Ab was determined by the number of migrating cells/well based on three blinded readings per each quadruplicate well ( Fig. 2A) 
IL-18 is primarily chemotactic for HMVECs
The checkerboard analysis was performed with the chemotaxis assay using increasing concentrations of IL-18 in the cell suspensions at the bottom of the chamber as well as in the top of the chamber. A representative assay of three is shown (Fig. 2B) . The concentrations were chosen for their known induction of HMVEC migration, starting at 1 nM, although the effect of 100 nM may not have been greatly dampened by the addition of 1 or 10 nM on the opposide side of the membrane. There was evidence of some HMVEC migration induced by the presence of IL-18 within the cell suspension, which exceeded that by PBS, reflecting a chemokinetic contribution. However, the presence of equivalent concentrations of IL-18 on either side of the membrane reduced the resultant migration to levels closer to PBS control. These data suggest a primarily chemotactic effect of IL-18 on HMVEC migration.
IL-18 contributes to RA SF-induced HMVEC migration
To determine the relative contribution of IL-18 to RA SF-induced HMVEC migration, we preincubated RA SF samples with neutralizing goat anti-human IL-18 Ab or nonspecific isotype-matched control goat IgG Ab, at a concentration of 25 g/ml for 1 h before and during 2 h of the assay. We found significant inhibition of RA SF-induced HMVEC migration with anti-IL-18 Ab, compared with nonspecific Ab (Fig. 3) . The inhibition of HMVEC migration after neutralization of the RA SF samples (n ϭ 4) with the anti-IL-18 Ab (13.5 Ϯ 2.9 cells/well) was 68 Ϯ 5% compared with sham neutralization with the control IgG Ab (41.5 Ϯ 4.3 cells/ well). HMVEC migration with control IgG was equivalent to RA SF alone (40.6 Ϯ 1.4 cells/well) ( p Ͻ 0.05). These findings suggest a prominent role for IL-18 in RA SF-induced HMVEC migration.
Contribution of IL-18, IL-8, and ENA-78 to RA SF-induced HMVEC migration
To compare the relative contribution to RA SF-induced HMVEC migration, we preincubated four different RA SF samples with neutralizing Abs to IL-18, IL-8, or ENA-78 (Fig. 4) . Immunodepletion of IL-18 resulted in a similar percentage of HMVEC migration inhibition (68 Ϯ 5%) as immunodepletion of IL-8 (64 Ϯ 7%). However, immunodepletion of IL-18 resulted in a 1.6-fold greater percent inhibition than immunodepletion of ENA-78 (43 Ϯ 6%). Values shown are means generated from four different RA SF patient samples and are significant compared with isotype-matched control Ab ‫,ء(‬ p Ͻ 0.05). Inhibition was not further enhanced with combinations of neutralizing Abs to IL-18 and either IL-8 or ENA-78 (62 Ϯ 3% and 70 Ϯ 3%, respectively).
Comparison of IL-18-induced HMVEC migration with chemokine-induced migration by IL-8 and ENA-78
The neutralization of IL-18 present in RA SF reduced SF-induced HMVEC migration to a similar or greater degree as neutralization of IL-8 or ENA-78, respectively. We compared the bioactivities of these recombinant human cytokines in the HMVEC migration assay. The dose responses were generated from three different experiments, and a representative assay is shown (Fig. 5) . IL-18 and ENA-78 induced HMVEC migration to a similar degree at the lower concentrations 0.1-10 nM. IL-18 exceeded the effect of ENA-78 at higher concentrations (10 -100 nM). In comparison, IL-8 showed greater effect on HMVEC migration at the lower and higher doses compared with IL-18 and ENA-78, which had more comparable bioactivities. Overall, assaying a wide range of concentrations, it appears that IL-8 is a more potent angiogenic agent than IL-18, which is of greater potency than ENA-78.
IL-18 induces HMVEC migration via ␣ v ␤ 3 integrin
To determine the mechanism by which IL-18 mediates angiogenesis, we hypothesized that IL-18 may act through integrins present on HMVECs. TNF-␣ is angiogenic in part via its action on integrin ␣ v ␤ 3 (34) . Thus, we examined whether blocking ␣ v ␤ 3 would inhibit IL-18-induced angiogenesis in the HMVEC migration assay. HMVECs were first incubated with anti-␣ v ␤ 3 Ab or nonspecific control IgG at 25 g/ml for 1 h before and during the chemotaxis assay. IL-18 (10 nM) was then used to stimulate HMVEC migration, and comparison was made with the control stimulants bFGF and TNF-␣. To illustrate a contrasting mechanism, VEGF was also used as another stimulant, which would not be expected to be inhibited by blocking ␣ v ␤ 3 , since the angiogenic ability of VEGF is thought to occur via the integrin ␣ v ␤ 5 (42) . Blocking HMVEC ␣ v ␤ 3 resulted in significant inhibition of IL-18-induced cell migration comparable with that seen with control (Fig. 6) . The same effect was seen with 25 or 10 g/ml blocking Ab concentration. Significant inhibition of cell migration by blocking HMVEC ␣ v ␤ 3 before stimulation with bFGF and TNF-␣ was also demonstrated, while no change in cell migration occurred after stimulation with VEGF. Shown are the representative data from three separate assays.
Effect of IL-18 on endothelial cell proliferation
The effect of rhIL-18 on endothelial cell proliferation was assessed using varying concentrations of IL-18 (10 Ϫ6 to 100 nM) to stimulate HMVEC growth. Control stimulation with bFGF (10 Ϫ5 to 10 nM) demonstrated an expected 2-fold increase in HMVEC proliferation. However, IL-18 did not directly stimulate or inhibit HMVEC proliferation on repeated assays (n ϭ 4), but behaved similarly to PBS control. The time point of 72 h at which cell growth was measured was selected when control bFGF-induced proliferation was optimal. Additionally, proliferation curves for HMVECs were determined for bFGF, media alone, and IL-18; and measurements were compared in the log proliferation phase (Fig. 7) .
IL-18 induces angiogenesis in Matrigel in vitro
Endothelial cell tube formation in Matrigel is one measure of angiogenesis in vitro. The role of IL-18 in angiogenesis was assessed by determining the induction of HMVEC tube formation on Matrigel matrix plated onto eight-well chamber slides. Tube-like structures formed after a 16-h incubation in the presence of IL-18, whereas grossly fewer tubes formed with PBS control (Fig. 8) . 
IL-18 induces angiogenesis in Matrigel in vivo
The angiogenic role of IL-18 in vivo was assessed by examining the effect of IL-18 on blood vessel growth in the Matrigel plugs in mice. The Matrigel plugs containing IL-18 (10 nM) induced significantly greater angiogenesis than control PBS. Histology illustrates the difference qualitatively in the representative photomicrographs of Masson trichrome-stained sections (ϫ50 magnification) (Fig. 9A) . Marked new blood vessel growth can be seen in the IL-18-containing plugs (left panel) compared with the control (right panel). Five Matrigel plugs were embedded with stimulus for each test group. The hemoglobin content of the 10 nM and 1 nM IL-18-containing plugs was 52-fold and 64-fold higher, respectively, than that for PBS control ( (n ϭ 3 assays) . There was significant suppression of IL-18-induced HMVEC migration after ␣ v ␤ 3 blockade, as was seen with bFGF and TNF-␣. VEGF served as a negative control stimulant. Ab concentrations were 25 g/ml.
FIGURE 7. IL-18 does not affect HMVEC proliferation. Varying concentrations of rhIL-18 (10 Ϫ6 -100 nM) were used to assess the effect on HMVEC proliferation, which was compared with that of control bFGF (10 Ϫ5 -10 nM) and nonstimulated PBS controls. Cell growth was measured as absorbance readings at 72 h, during the optimal phase of growth. An expected 2-fold increase was demonstrated after 100 pM and 1 nM bFGF stimulation, with significant difference from PBS controls seen also at 10 nM bFGF ‫,ء(‬ p Ͻ 0.05). However, the effect of IL-18 was similar to nonstimulated PBS controls on repeated assays, and shown is a composite of the data (n ϭ 3). 
IL-18 induces angiogenesis in Matrigel in vivo independently of TNF-␣
To examine the angiogenic effect of IL-18 in the presence of neutralizing anti-TNF-␣ Ab, Matrigel plugs containing 10 nM IL-18 and 25 g/ml anti-TNF-␣ Ab or isotype-matched control IgG were injected into mice (n ϭ 18 per group). After 7 days incubation, the mean normalized hemoglobin contents were determined, and there was no significant difference between the two groups: 2.67 Ϯ 0.62 g/dl/(mg) for the IL-18 plus IgG-containing plugs vs 2 Ϯ 0.31 g/dl/(mg) for the IL-18 plus anti-TNF-␣-containing plugs (Fig.  10) . The hemoglobin content of the 10 nM IL-18 plus IgG-containing plugs was 3.7 times greater than that of PBS control.
IL-18 induces angiogenesis in the sponge granuloma model in vivo
To examine whether IL-18 induced inflammatory angiogenesis in vivo, the sponge granuloma model was used. In this model, angiogenesis was measured as increased blood vessel growth in discs made from polyvinyl alcohol foam sponges containing either IL-18 or control stimulant aFGF and implanted into mice. After 11 days, there was a significant increase in blood vessel growth with IL-18 stimulation vs PBS control (Fig. 11) . A 5-fold increase in angiogenesis with IL-18 (10 nM) was demonstrated by greater hemoglobin concentrations measured with tetramethylbenzidine, and the hemoglobin value induced by IL-18 was even greater than that for aFGF, which resulted in a 4-fold increase: 5.77 Ϯ 1.21 g/dl/(mg) for IL-18, 4.45 Ϯ 1.81 g/dl/(mg) for aFGF, and 1.13 Ϯ 0.29 g/dl/(mg) for PBS ( p Ͻ 0.05).
Discussion
In this study, we examined the potential role of IL-18 in mediating angiogenesis through its action in both in vitro and in vivo bioassays. We found evidence that IL-18 possesses angiogenic properties, a novel function for IL-18. While IL-18 has been implicated in RA pathogenesis, IL-18's complex array of functions and mechanisms by which it promotes inflammation has not been fully elucidated. IL-18 is up-regulated in the SF and serum from RA patients compared with osteoarthritis patients (21) . The use of IL-18 has also been shown to facilitate the development of erosive, inflammatory arthritis when administered in murine type II collageninduced arthritis (25) . IL-18 promotes articular Th1 responses and is thus important in the pathophysiology of RA (21) .
Integral to the inflammation in RA is the process of angiogenesis. We found that IL-18 induced endothelial migration in the HMVEC migration assay, which is one aspect of angiogenesis in vitro. IL-18 induced HMVEC migration in the nanomolar range in a concentration-dependent manner, between 1 and 100 nM, with 100 nM IL-18 achieving a comparable degree of cell migration to 60 nM bFGF, a potent chemotactic stimulus. We were able to verify this finding by neutralizing the rhIL-18 with specific anti-IL-18 Ab, thereby blocking its chemotactic function compared with blocking with control-nonspecific IgG. Checkerboard analysis demonstrated a primarily chemotactic property of IL-18, whose effect is dependent on a concentration gradient rather than random chemokinesis. With the knowledge that RA SF is highly chemotactic and that IL-18 is elevated in RA SF, we examined the contribution of RA SF IL-18 to endothelial cell migration. Four different RA SFs immunodepleted of IL-18 resulted in a 68 Ϯ 5% decrease in endothelial migration. This finding supports a potent role of IL-18 in endothelial cell migration in RA.
To compare the contribution of RA SF IL-18 with other mediators of RA SF that also induce endothelial cell migration, we further immunodepleted RA SFs of IL-18 alone and in combination with the chemokines IL-8 or ENA-78 (12, 43) . IL-18 appeared to account for a significant portion of chemotactic activity for HMVECs in the SFs comparable with that by IL-8. The contribution by IL-18 was 1.6-fold greater than that by ENA-78. Combining immunodepletions of IL-18 and IL-8 or ENA-78 did not augment suppression of HMVEC migration. The lack of further suppression suggests that inhibiting the effect of one of these cytokines may be blocking common pathways involved in HMVEC migration. IL-18 accounted for approximately two-thirds of the migrating activity of HMVECs in RA SFs. These results indicate that IL-18 is one of the main mediators of RA SF-induced HM-VEC migration.
A direct comparison of the HMVEC-migrating activity of the rh IL-18 with that of the chemokines rhIL-8 and rhENA-78 in the HMVEC migration assay revealed that IL-8 was a more potent agent than IL-18, which was more potent than or comparable with ENA-78.
IL-18 is also ascribed many inflammatory functions that would be consistent with a role in angiogenesis. For instance, IL-18 stimulates the production of other proangiogenic cytokines, such as TNF-␣, IL-1␤ and IL-8, from human PBMCs, the responding cells being predominantly resting T cells and NK cells. IL-18's stimulation of the chemokine IL-8 has also been shown in the macrophage cell line derived from histiocytic lymphoma cell, U937, and the myelomonocytic leukemia cell line, KG-1 (44, 45) , to produce IL-8 and other C-X-C chemokines. Besides its direct angiogenic role, other potential mechanisms of the angiogenic function of IL-18 may be through IL-8 and other angiogenic cytokines that it up-regulates. Indeed, IL-18 exerts an inflammatory cytokine cascade in the mixed PBMC population by stimulating the constitutive expression of IL-18R on NK cells and lymphocytes, which leads to TNF-␣ production, ultimately stimulating macrophage IL-1␤ and IL-8 production (19) . In turn, treatment with IL-1␤ and TNF-␣ of RA synovial fibroblast cultures, not constitutively expressing IL-18, induced IL-18 gene and protein production, suggesting a feedback interaction to promote Th1 cytokine and cell development in RA (21) .
IL-18 promotes inflammation, not only via other cytokine actions as above, but also through the promotion of other inflammatory mediators, some of which are themselves implicated in angiogenesis. IL-18 stimulates the expression of the soluble adhesion molecule ICAM-1 on monocytic cell lines (46) , and we have found that IL-18 up-regulates the expression of VCAM-1 on RA synovial fibroblasts (47) . Soluble VCAM-1 is potently angiogenic (14) , and it may be that IL-18 also acts to stimulate RA fibroblast VCAM-1 expression, hence amplifying the angiogenic response.
To elucidate a mechanism by which IL-18 mediates angiogenesis, we examined the potential role of the integrin ␣ v ␤ 3 in HMVEC migration. Endothelial cell invasion, migration, and proliferation are regulated in part by the integrin family of cell adhesion molecules, and we have shown that ␣ v ␤ 3 is up-regulated on RA compared with osteoarthritic or normal synovial blood vessels (48) . We therefore hypothesized that like bFGF and TNF-␣ (34), IL-18 may also act via this integrin in angiogenesis. After blocking ␣ v ␤ 3 on HMVECs with specific anti-␣ v ␤ 3 Ab, the degree of IL-18-induced cell migration was inhibited by 34% compared with blocking with isotype-matched control Ab. ␣ v ␤ 3 antagonists have successfully modulated angiogenesis in a rabbit model of synovitis (49) . Targeting IL-18, which appears to function in part through this integrin, could be an alternative therapeutic approach for RA.
Endothelial cell proliferation is another aspect of angiogenesis. We did not demonstrate direct inhibition or enhancement of basal endothelial cell (HMVEC) proliferation, which is in contrast to previous reports of the antimitogenic activity of IL-18. IL-18 at 1-10 nM concentration has been reported to inhibit FGF-2-induced capillary endothelial cell proliferation (50) . However, the effect of IL-18 on basal proliferation, as examined in our study, was not explored. This group also found that murine, not human, IL-18 suppressed FGF-2-induced corneal neovascularization in mice, although the IL-18 was administered by i.p. injections, and it is unclear whether local rather than systemic treatment would have induced divergent results. Interestingly, they also found that IL-18 suppressed angiogenesis in the chick chorioallantoic membrane model. Our finding that IL-18 did not induce HMVEC proliferation is consistent with results obtained for other angiogenic mediators, such as soluble VCAM-1 or soluble E-selectin, which also do not induce endothelial proliferation (14) .
Consistent with the chemotactic properties of IL-18, we also showed IL-18 induction of HMVEC tube formation in Matrigel matrix in vitro. The degree of tube formation by IL-18 at 1 nM was comparable with the stimulant PMA (50 mM), a potent inducer of HMVEC differentiation and tube formation (51) . In the Matrigel in vivo mouse angiogenesis model, IL-18 also stimulated actual blood vessel formation, which was visibly in excess of control. The potency of IL-18 relative to other angiogenic stimulants in this assay can be assessed, since 1 nM (or 18 ng/ml) IL-18 produced results similar to that induced by 1 ng/ml aFGF, which is clearly one of the strongest angiogenic stimuli. By comparison, an excess of 100-fold more bFGF would be required to produce the same effect in this assay as 1 ng/ml aFGF (0.86 g/dl vs 1.30 g/dl hemoglobin), and 10-fold more TNF-␣ (10 ng/ml hemoglobin) would be expected to produce twice the effect as 1 ng/ml aFGF (2.3 g/dl vs 1.3 g/dl hemoglobin) (37) .
The Matrigel in vivo assay also allowed for another examination of a potential mechanism behind the angiogenic activity of IL-18. The angiogenic effect of IL-18 in the presence of anti-TNF-␣ Ab was evaluated by adding IL-18 and neutralizing anti-TNF-␣ Ab to the Matrigel before injection. Although the endothelial cells were the target of the effect of IL-18 in cell migration and tube formation observed in the earlier assays, the new blood vessel formation in the Matrigel plug could involve cellular targets other than endothelial cells, at least indirectly. In our hands, blocking the local TNF-␣ did not significantly alter the effect of IL-18 on Matrigel plug hemoglobin content. However, it is not clear whether systemic inhibition of TNF-␣ would have diminished the effect of IL-18. In addition, the downstream effect of IL-18 on PBMCs, lymphocytes, and other cells via up-regulation of other cytokines cannot be overlooked. The various mediators known to orchestrate the angiogenic process may function in part through common pathways. Although redundancy in the system exists and serves to maintain the angiogenic state characteristic of certain physiologic or pathologic conditions, evidence from clinical trials clearly demonstrates that blocking one key element through treatment targeting TNF-␣ alone reduced RA disease activity (52) . Further studies examining potential mechanisms of angiogenesis, including common signaling pathways, cell adhesion, and up-regulation of cytokines, integrins, and other mediators, may shed light on the significance of the current findings.
The sponge angiogenesis system allows testing of the effect of various antagonists and agonists on the proliferation of blood vessels and stroma, provides histological and quantitative information, and is easily reproducible. This system applied to mice was suitable to test the independent effect of IL-18 on angiogenesis, and specifically, new blood vessel formation, which this assay measures by virtue of the constant sample area of the disc and the planar growth of the vessels (41) . IL-18 at 10 nM strongly induced angiogenesis, as measured by a 5-fold increase in the amount of hemoglobin over control, similar to the 4-fold increase seen with the positive control stimulant aFGF (1 nM). This finding not only confirms our results from the Matrigel plug in vivo assay, but it establishes IL-18 as a direct angiogenic stimulus.
In summary, we found that IL-18 induces endothelial cell chemotaxis, and that IL-18 accounts for a significant portion of the vascular migration characteristic of RA SF. This contribution is independent of that made by the chemokines IL-8 and ENA-78 also found in RA SF. One mechanism for IL-18-induced HMVEC migration is through the integrin ␣ v ␤ 3 , placing IL-18 in company with TNF-␣ and bFGF, which also act in part through this specific integrin. In our hands, IL-18 did not affect basal endothelial cell proliferation. We demonstrated the ability of IL-18 to induce tube formation in Matrigel in vitro as well as significant blood vessel formation in the Matrigel plug in vivo. An attempt to block the effect of TNF-␣ present at the angiogenesis site with neutralizing Abs in the Matrigel plug did not significantly diminish the angiogenic effect of IL-18 within the plug. Finally, IL-18 induced neovascularization in the sponge disc angiogenesis model in mice. These findings support the notion of IL-18 as a potent angiogenic stimulus, with the capacity to mediate vascular migration and new blood vessel formation in the development of inflammatory and angiogenesis-driven disease, such as RA. Ultimately, this evidence for a novel angiogenic function of IL-18 may lend itself to potential therapeutic targets in the treatment of RA.
